EnChannel Medical announced today that it agreed to acquire the AcQMap platform assets from Acutus Medical.
This deal centers around the AcQMap high-resolution imaging and mapping platform from Acutus. It also includes substantive intellectual property, quality and regulatory documentation and clinical data. With the agreement, EnChannel receives a limited number of AcQMap systems and associated catheter devices for R&D purposes.
Acutus announced at the end of 2024 that it planned a realignment of resources and operational downsizing. The company continues to comply with its remaining obligations to Medtronic for the production of left-heart access products. Acutus sold its left-heart access portfolio to Medtronic for $50 million.
In March, Acutus said an exit from the electrophysiology (EP) mapping and ablation business came as part of the realignment.
EnChannel says the acquisition strengthens its IP portfolio with new second- and third-generation non-contact mapping technologies. AcQMap uses voltage-to-charge-density mapping for improved spatial resolution and accuracy. EnChannel itself develops a holistic platform unifying magnetic-impedance navigation, intracardiac echocardiography, full-chamber 5D action-potential mapping, and mid-voltage (<1000 V) pulsed-field ablation. It aims to deliver safe and personalized treatment for patients with AFib.
“This strategic acquisition accelerates our mission to visualize and treat AF with unprecedented efficiency and precision,” said Jun Feng, CEO of EnChannel Medical. “By building on prior advancements and leveraging our proprietary technologies, we are shaping the future of persistent AF diagnosis and treatment.”
